Lixia Ma

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.

Journal: Frontiers in immunology
Published: June 29, 2026

Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.

Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.

Journal: Annals of hematology
Published: April 28, 2026

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Journal: Frontiers in immunology
Published: March 05, 2026

ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study.

ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study.

Journal: Transplantation and cellular therapy
Published: February 25, 2026

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Journal: Frontiers in immunology
Published: November 28, 2025

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Journal: Discover oncology
Published: November 25, 2025

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Journal: Blood cancer journal
Published: November 01, 2025

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.

Journal: Frontiers in medicine
Published: October 24, 2025

Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy.

Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy.

Journal: Cancer immunology, immunotherapy : CII
Published: August 12, 2025

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation.

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation.

Journal: Frontiers in oncology
Published: March 11, 2025

Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma.

Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma.

Journal: Annals of hematology
Published: February 19, 2025

CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-T.

CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-T.

Journal: Transplantation and cellular therapy
Published: February 16, 2025
Showing 1-12 of 23

Last Updated: 09/26/2026